All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 44 points (0.3%) at 17,560 as of Monday, March 28, 2016, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,693 issues advancing vs. 1,250 declining with 166 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include

Ionis Pharmaceuticals

(

IONS

), down 7.3%,

Alkermes

(

ALKS

), down 3.9%,

Endo International

(

ENDP

), down 3.5%,

Perrigo

(

PRGO

), down 2.8% and

Mylan

(

MYL

), down 1.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Valeant Pharmaceuticals International

(

VRX

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Valeant Pharmaceuticals International is down $2.39 (-7.7%) to $28.70 on heavy volume. Thus far, 15.4 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 16.3 million shares. The stock has ranged in price between $28.26-$30.60 after having opened the day at $30.38 as compared to the previous trading day's close of $31.09.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $10.7 billion and is part of the health care sector. Shares are down 69.4% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Valeant Pharmaceuticals International a buy, 3 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Celgene

(

CELG

) is down $0.77 (-0.8%) to $99.77 on light volume. Thus far, 1.3 million shares of Celgene exchanged hands as compared to its average daily volume of 6.6 million shares. The stock has ranged in price between $98.99-$100.99 after having opened the day at $100.43 as compared to the previous trading day's close of $100.54.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. Celgene has a market cap of $78.6 billion and is part of the health care sector. Shares are down 16.1% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Pfizer

(

PFE

) is down $0.16 (-0.5%) to $29.92 on light volume. Thus far, 12.6 million shares of Pfizer exchanged hands as compared to its average daily volume of 41.4 million shares. The stock has ranged in price between $29.80-$30.22 after having opened the day at $30.09 as compared to the previous trading day's close of $30.08.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $186.0 billion and is part of the health care sector. Shares are down 6.8% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts that rate Pfizer a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Pfizer Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).